← Back to Search

Photosensitizer

Visudyne for Retinal Vascular Disorder (ICGguidedPDT Trial)

N/A
Waitlist Available
Led By Lawrence A. Yannuzzi, M.D.
Research Sponsored by Manhattan Eye, Ear & Throat Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1-2 years
Awards & highlights

ICGguidedPDT Trial Summary

The purpose of this research is to use an approved drug(Visudyne) for neovascular age-related macular degeneration, which is essentially choroidal neovascularization for permeability and vascular proliferation for the retinal circulation, to treat another permeable abnormality - retinal capillary abnormalities - located eccentric to the central portion of the macula or in the foveal region.

Eligible Conditions
  • Retinal Vascular Disorder

ICGguidedPDT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1-2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1-2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Improvement and/or stabilization of disease.

Side effects data

From 2017 Phase 4 trial • 333 Patients • NCT02120950
16%
Viral upper respiratory tract infection
6%
Vitreous floaters
6%
Conjunctival haemorrhage
4%
Dry eye
4%
Intraocular pressure increased
4%
Hypertension
4%
Visual acuity reduced
3%
Retinal pigment epithelial tear
2%
Ocular hypertension
1%
Thyroid neoplasm
1%
Lumbar vertebral fracture
1%
Inguinal hernia strangulated
1%
Haematuria
1%
Fall
1%
Varicose vein
1%
Large intestine polyp
1%
Osteonecrosis
1%
Subdural haematoma
1%
Iron deficiency
1%
Depression
1%
Colon cancer
1%
Osteoarthritis
1%
Neoplasm
1%
Transcatheter arterial chemoembolisation
1%
Cataract
1%
Large intestine perforation
1%
Scapula fracture
1%
Ileus
1%
Death
1%
Joint dislocation
1%
Rib fracture
1%
Upper gastrointestinal haemorrhage
1%
Animal bite
1%
Gastric cancer
1%
Metastases to lung
1%
Ureterolithiasis
1%
Radius fracture
1%
Angina pectoris
1%
Angina unstable
1%
Arrhythmia
1%
Cardiac failure congestive
1%
Coronary artery stenosis
1%
Stress cardiomyopathy
1%
Ear infection
1%
Endophthalmitis
1%
Septic shock
1%
Femoral neck fracture
1%
Hip fracture
1%
Traumatic haemothorax
1%
Exostosis
1%
Adenocarcinoma gastric
1%
Prostate cancer
1%
Cystocele
1%
Acute pulmonary oedema
1%
Erythema
100%
80%
60%
40%
20%
0%
Study treatment Arm
Aflibercept + Sham PDT
Aflibercept + Active PDT
Aflibercept (Non-randomized)

ICGguidedPDT Trial Design

1Treatment groups
Experimental Treatment
Group I: VisudyneExperimental Treatment1 Intervention
Visudyne half fluence- 1 treatment with the possibility of a second treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Verteporfin
FDA approved

Find a Location

Who is running the clinical trial?

Manhattan Eye, Ear & Throat HospitalLead Sponsor
16 Previous Clinical Trials
165 Total Patients Enrolled
Lawrence A. Yannuzzi, M.D.Principal InvestigatorNorthshore LIJ/MEETH
1 Previous Clinical Trials

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
ICG-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities: A Pilot Study
2013. "ICG-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities: A Pilot Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01974622.
All > Photodynamic Therapy
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top